RxPG News XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!  

Medical Research Health Special Topics World
 
  Home
 
 Careers 
 Dental
 Medical
 Nursing
 
 Latest Research 
 Aging
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Psychiatry
 Public Health
 Radiology
 Rheumatology
 Surgery
 Urology
 Alternative Medicine
 Medicine
 Epidemiology
 Sports Medicine
 Toxicology
 
 Medical News 
 Awards & Prizes
 Epidemics
 Health
 Healthcare
 Launch
 Opinion
 Professionals
 
 Special Topics 
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
 
 DocIndia 
 Reservation Issue
 Overseas Indian Doctor

Last Updated: May 20, 2007 - 10:48:48 AM
News Report
America Channel

subscribe to America newsletter
America

   EMAIL   |   PRINT
Brazil bypasses US giant for Indian drugs
May 5, 2007 - 12:08:05 PM
Minister of Health Jose Gomes Temporao then advised President Lula to sign the decree establishing the 'compulsory license' for the anti-HIV drug allowing Brazil to import the drug at lower prices from other overseas suppliers or even produce it locally.

Article options
 Email to a Friend
 Printer friendly version
 America channel RSS
 More America news
[RxPG] Rio De Janeiro, May 5 - Brazilian President Luiz Inacio Lula da Silva has allowed his country to ignore US pharmaceutical giant Merck's patent on AIDS drug Efavirenz and opted for a cheaper generic alternative from India.

With a decree he signed Friday, Brazil will be able to import generic versions of Efavirenz from three companies in India - and the price for the drugs will be 72 percent lower than the price charged by Merck.

The Brazilian ministry of health had been negotiating with Merck for three years to bring down the Efavirenz price.

Lula had criticized Merck for charging higher prices to Brazil than to other countries, an attitude he regarded as 'disrespectful'.

According to the ministry, Merck charges Brazil $1.59 per capsule but Thailand pays only 64 cents.

Merck initially proposed a 2 percent reduction in the Efavirenz price, which the Brazilians rejected.

On April 25, the Brazilian government classified the drug as one 'of public interest' and asked Merck to present another proposal within seven days.

Merck offered a 30 percent price cut but the Brazilian authorities still considered it unsatisfactory because it was possible to buy the generic version of the medicine for as low as $0.45.

Minister of Health Jose Gomes Temporao then advised President Lula to sign the decree establishing the 'compulsory license' for the anti-HIV drug allowing Brazil to import the drug at lower prices from other overseas suppliers or even produce it locally.

Health authorities expect the new measure to save up to $30 million in 2007, as 75,000 of the 200,000 AIDS patients whose treatment is funded by the government are expected to use Efavirenz by the end of the year.





Related America News
Run to support fight against kidney disease
Mexican footballer banned for life for doping
Ranbaxy gets FDA approval for allergy drug
Sunita Williams assembles special space walk tool
Simpson misses charity benefit
Chronic pain may impair your memory
Silicon Valley companies provide technology for latest 'Shrek' film
Israel threatens to take 'other military actions' in Gaza
'World bank can now refocus on poverty in South Asia'
Microsoft buys ad-firm Aquantive for $6 bn

Subscribe to America Newsletter
E-mail Address:

 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
© All rights reserved 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us